Thus, ERRα serves as a metabolic integrator between gut-derived cues and liver physiology, and its therapeutic targeting—through agonists, prebiotics, or metabolic interventions—holds promise for treating MASLD, MASH, and related metabolic disorders. The gene discussed is ESRRA; the disease is metabolic dysfunction-associated steatotic liver disease.